Adebayo Alonge founded RxAll, a pioneering company utilizing artificial intelligence to combat the pervasive issue of counterfeit drugs in Africa. Alonge’s personal ordeal—a 21-day coma over 15 years ago due to fake medicine in Nigeria—galvanized his mission. This life-threatening experience propelled him through pharmacy and business schools, culminating in the establishment of RxAll with co-founder Ankur Kapadia, later joined by Amy Kao and Wei Liu. Their innovation: an AI-powered platform employing a handheld spectrometer to authenticate medicines, a critical development in public health.
The global scale of counterfeit pharmaceuticals is staggering. The World Health Organization (WHO) estimates this illicit market to be worth between $75 billion and $200 billion annually. Some analysts place this figure even higher, ranging from $200 billion to $432 billion, positioning it as one of the foremost illicit activities globally. In low- and middle-income countries, a concerning one in ten medicines is estimated to be counterfeit, posing severe health risks to unsuspecting patients.
Africa bears a disproportionate burden of this crisis. The WHO reports that 700,000 Africans die annually from consuming fake anti-malarial or tuberculosis drugs alone. Other estimates suggest over 100,000 annual deaths across the continent from counterfeit medicines. The United Nations Office on Drugs and Crime (UNODC) tragically estimates up to 500,000 deaths in sub-Saharan Africa each year due to fake medicines, including 267,000 linked to fake anti-malarials and 169,271 to fake antibiotics for childhood pneumonia. This constitutes a profound public health catastrophe.
RxAll’s flagship device, the RxScanner, is a handheld authenticator designed to help patients and pharmacies verify drug safety and purity. This device has demonstrated remarkable efficacy, achieving a reported accuracy rate of 96.7% in 2019, and even 99% in earlier tests. Such precision is particularly impressive for a device significantly more affordable than traditional laboratory equipment. By March 2019, RxAll had deployed approximately 70 RxScanner devices to food and drug administration agencies in five African countries, alongside 200 pharmacies in Nigeria and Kenya. These deployments led to the detection and prevention of over 60,000 substandard drugs from reaching consumers, averting countless potential tragedies.
To sustain its vital mission, RxAll has successfully secured significant funding. The company raised $900,000 in pre-seed funding in late 2020, followed by a $3.15 million seed round in 2021. This seed round was notably led by SOSV’s HAX, Launch Africa, and Keisuke Honda’s KSK fund. By September 2024, RxAll had accumulated approximately $7 million in total funding. These investments fuel the company’s ambitious expansion plans, which included reaching 14 countries by the end of 2021 and targeting five additional African markets by 2028. Furthermore, RxAll is exploring expansion into Southeast Asia, North America, and South America, acknowledging the global nature of the counterfeit drug problem.
The success of RxAll underscores the burgeoning importance of small AI models and edge AI. These technologies enable local data processing directly on devices, circumventing the need for constant cloud connectivity. This capability is invaluable in regions with unreliable internet infrastructure and where data privacy is paramount. The global edge AI market is experiencing explosive growth, with projections from Grand View Research anticipating it to reach $118.69 billion by 2033. Fortune Business Insights offers an even more optimistic outlook, forecasting a market size of $445.75 billion by 2034, driven by a compound annual growth rate (CAGR) of 32.5% from 2026 to 2034. The hardware segment is a dominant force within this industry, commanding a 51.8% revenue share in 2025. The edge AI hardware market, valued at $22.6 billion in 2025, is projected to expand to $89.4 billion by 2035, indicating substantial investment in localized AI capabilities.
Small Language Models (SLMs) represent another critical facet of this technological shift. This sector alone is valued at $0.93 billion in 2025 and is projected to grow to $5.45 billion by 2032. SLMs are capable of delivering 80-90% of the functionalities of much larger models while operating entirely on-device. This innovation is transformative for numerous applications requiring rapid, local processing, extending far beyond healthcare. While North America currently holds the largest market share in edge AI, accounting for 36% in 2025, the Asia Pacific region is anticipated to exhibit the fastest growth.
Beyond detection, RxAll has developed a comprehensive digital platform that allows pharmacies to order authentic stock directly from verified suppliers. The company also offers RxPay, a payment wallet designed to assist pharmacies with financing and inventory management. This integrated approach aims to establish a secure and transparent pharmaceutical supply chain. Furthermore, evolving regulatory landscapes, including increased emphasis on post-marketing surveillance and the digitization of independent pharmacies, are creating favorable market conditions for companies like RxAll.
The profound impact of this technology, driven by small AI models on edge devices, is undeniable. It exemplifies how artificial intelligence can transcend theoretical applications to solve critical, real-world problems that directly save lives. This tangible application of AI is a testament to its transformative potential. On a related note, I acquired NVIDIA (NVDA) stock on December 15, 2021, at $28.50, with a target sell price of $200.00. The relentless advancement of AI and the foundational hardware supporting it suggest continued growth in this sector.